Navigation Links
Amgen Announces Positive Top-Line Results From 52-Week Phase 3 DESCARTES Study Of Evolocumab (AMG 145) In Patients With High Cholesterol
Date:12/19/2013

nt of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and products liability claims. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.

In addition, sales of our products are affected by the reimbursement policies imposed by third-party payors, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursemen
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Amgen Announces 2014 First Quarter Dividend
2. Amgen To Present At The Oppenheimer 24th Annual Healthcare Conference
3. Amgen To Webcast Investor Meeting At Upcoming American Heart Association Scientific Sessions 2013
4. Amgens Third Quarter 2013 Revenues Increased 10 Percent To $4.7 Billion And Adjusted Earnings Per Share (EPS) Increased 16 Percent To $1.94
5. Amgen Acquires Filgrastim Franchise Rights From Roche In 100 Markets
6. Amgen Successfully Completes Onyx Pharmaceuticals Tender Offer
7. Amgen and Onyx Pharmaceuticals Announce Early Termination of HSR Waiting Period for Amgens Acquisition of Onyx
8. Amgen And Cytokinetics Announce The First Presentation Of Data From Phase 2 ATOMIC-AHF Study Of Omecamtiv Mecarbil
9. Amgen To Participate At Citis 8th Annual Biotech Conference
10. Healthcare Briefing - Leading Medical Companies in the News: Bio-Solutions, Catalyst Pharmaceutical, MannKind, Amgen, Accuray
11. Amgen to Highlight New Data at Upcoming ESC Congress 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Pomerantz LLP has filed a class action ... EDAP ) and certain of its officers.  ... Southern District of New York , ... class consisting of all persons or entities who purchased ... 2014, inclusive (the "Class Period"). This class action seeks to ...
(Date:8/29/2014)... Thoratec Corporation (NASDAQ: THOR ), ... to save, support and restore failing hearts, said today ... Global Healthcare Conference on Wednesday, September 10. ... Officer, will provide an update on the company, beginning ... Daylight Time).   A webcast of the ...
(Date:8/29/2014)... 2014 Research and Markets  has announced the ... 2014" report to their offering. The ... of the largest segments of pharmaceuticals industry. The numbers of ... available therapies were unable to meet the market requirements. There ... CNS disorder, especially over the past two decades. The market ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 3US CNS Disorders Drug Pipeline Insight 2014 2
... Tenn. , Jan. 20 Cumberland Pharmaceuticals Inc. ( ... ) Injection, an intravenous form of ibuprofen, to Haitian relief effort. ... for the treatment of pain and reduction of fever in ... continue to deteriorate, Caldolor is expected to help those suffering from ...
... , , LOS ANGELES , ... that it has joined forces with New Jersey -based ... create the nation,s first IVF insurance program. The Assisted Reproduction ... financial solutions for the ever-rising costs of In Vitro Fertilization ...
Cached Medicine Technology:Cumberland Pharmaceuticals Donates Caldolor(R) to Haitian Relief Effort 2Cumberland Pharmaceuticals Donates Caldolor(R) to Haitian Relief Effort 3New Life Agency, Inc. Joins Forces With The Diamond Institute and Walgreens Specialty Pharmacy to Introduce the Nation's First In Vitro Fertilization Insurance Program 2New Life Agency, Inc. Joins Forces With The Diamond Institute and Walgreens Specialty Pharmacy to Introduce the Nation's First In Vitro Fertilization Insurance Program 3
(Date:8/29/2014)... 2014 Healthpointe is proud to welcome ... Rodas will be practicing out of Healthpointe’s newest office ... of Healthpointe’s orthopedic team, Dr. Rodas is ... board-certified in occupational medicine. , Among Dr. Rodas’ ... Director of Raytheon, the world-class defense and aerospace company. ...
(Date:8/29/2014)... Healthpointe is pleased to provide ... students via Clinical Rotations. Physical Therapy ... Healthpointe providers and specialists throughout their daily clinical ... experience and learn professional preparation. , ... into several patient care techniques and expand their ...
(Date:8/29/2014)... August 29, 2014 Pursuing its deepest ... set to unveil a stunning new design that promises ... figures, the highly notable surrogacy platform has witnessed a ... over 13,000 visitors a month, the FindSurrogateMother.com community is ... toward one common goal — the precious gift of ...
(Date:8/29/2014)... trials based on administering antidepressants for acute and ... trials are needed to determine whether these drugs ... regular basis., Dr. Ian Gilron, a professor and ... of Anesthesiology, and his team of seven researchers ... of antidepressants for pain relief post-surgery would work ...
(Date:8/29/2014)... Grove Village, IL (PRWEB) August 29, 2014 ... innovator in hearing wellness solutions, is on its way ... 15-17 at the San Diego Convention Center to exhibit ... those who work in high-noise industrial environments. Etymotic’s safety ... the hottest wearable technology devices at the show. ...
Breaking Medicine News(10 mins):Health News:Dr. Anthony G. Rodas Joins Healthpointe Team at LAX Office 2Health News:Healthpointe is Now Offering Clinical Rotations for Chapman University Physical Therapy Students 2Health News:FindSurrogateMother.com Set to Unveil Stunning New Design as Member Sign-ups Increase by 42% since January 2Health News:FindSurrogateMother.com Set to Unveil Stunning New Design as Member Sign-ups Increase by 42% since January 3Health News:Antidepressants show potential for postoperative pain 2Health News:Etymotic’s Safe Listening Earphones and Earplugs Headed For The 2014 NSC Safety Expo 2
... and global IT giant Tata Consultancy Services (TCS) have ... a global drug development center in Mumbai. ... variety of services in clinical research, including clinical data ... ,"GSK has chosen to partner with TCS because of ...
... official figures.// ,Statistics for 2006 show ... which protects against measles, mumps and rubella, as against the national ... is an increase from the previous year, when the figure was ... 1988, but levels of uptake began to decline after 1998 when ...
... decided to crackdown on unethical doctors who accept gifts from ... entrance. ,This move follows the rocketing costs ... such tests. , According to the new law ... up to 5 years in jail, in terms of prosecution ...
... of persons infected with deadly viruses such as HIV and ... understand how. // , An independent inquiry is soon ... by almost 2000 hemophilia patients, via blood transfusions, in what ... of UK’s National Health Services. , The ...
... the “triple negative” type are destructive and lethal, and tend ... novel// study Published in the May 1, 2007 issue of ... occur commonly among women who are African American and Hispanic, ... socioeconomic status (SES). The study also showed that triple negative ...
... found that the most potent cholesterol-lowering drug is ... blood vessels that can lead to atherosclerosis. ... arteries compared to a placebo,” said John R.Crouse, ... at Wake Forest University School of Medicine. “The ...
Cached Medicine News:Health News:Scotland’s Parents Still a Little Wary of MMR Shot 2Health News:Inquiry into Past NHS Treatment Disaster 2Health News:'Triple Negative' Breast Cancers Seem to Affect the Young, Minority 2Health News:Cholesterol-lowering Drug Effective at Halting Early Atherosclerosis 2
Sprint Quattro Secure™ is a Steroid-Eluting, True Bipolar, Active Fixation ICD Lead....
TVL defibrillation leads have a patented coiled-coil design for faster, easier insertion and more precise intracardiac placement. Designed with an integrated bipolar design, the lead enables high-vol...
The TVL-ADX lead is a thin, high-performing defibrillation lead that offers a true bipolar configuration designed for smarter sensing and low defibrillation threshold for greater patient safety margi...
... SPL defibrillator lead features a ... the flexibility and maneuverability of ... the physician who prefers a ... the SPL lead also promotes ...
Medicine Products: